Actively Recruiting
OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding
Led by Chinese University of Hong Kong · Updated on 2026-03-18
236
Participants Needed
5
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In the management of patients with acute upper non-variceal upper gastrointestinal bleeding, further bleeding is the most important adverse factor predictive of mortality. In the United Kingdom Audit on acute upper gastrointestinal bleeding, clinical evidence of further bleeding was reported in 13% of patients following the first endoscopy and 27% of them died. The use of OTSC has emerged as an alternative before angiographic embolization(TAE) which is often considered most definitive. We propose to define the algorithm in the management of patients with refractory bleeding from their peptic ulcers or other non variceal causes. We hypothesize that endoscopic use of OTSC compares favourably with TAE and both lead to similar outcomes. An equivalence of the two modalities may mean that endoscopic application of OTSC should be attempted before TAE as often we need to document further bleeds with endoscopy and a second treatment should be instituted at the same time.
CONDITIONS
Official Title
OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with clear signs of acute upper gastrointestinal bleeding such as hematemesis, melena, or low blood pressure
- Bleeding lesion confirmed by endoscopy (including ulcers, dieulafoy's lesion, or others)
- Further bleeding (persistent or recurrent) after initial endoscopic treatment (thermal or hemoclips) as defined by an International Consensus Group
You will not qualify if you...
- Lack of full informed consent from the patient or a legal representative
- Age under 18 years
- Pregnant women
- Lactating women
- Known allergy to intravenous contrast agents
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Beijing friendship Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
2
the First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Actively Recruiting
3
Huaxi Hospital of Sichuan University
Chengdu, Sichuan, China
Actively Recruiting
4
Endoscopy Centre, Prince of Wales Hospital
Hong Kong, N.T., Hong Kong
Actively Recruiting
5
King Chulalongkorn Memorial Hospital
Bangkok, Bangkok, Thailand
Actively Recruiting
Research Team
Y
Yau Wong James Lau, MD
CONTACT
Y
Yuanyuan yu, phd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here